Skip to main content

References

📍 Where we are: The evidence base for the whole guide, gathered in one place.

Every inline citation in this guide — written as a bracketed marker like [1] — resolves here, grouped by chapter. The numbering on this page matches the [N] markers in each chapter.

Chapter 1 — From idea to patient: the whole journey​

  1. Shukla AA, Thömmes J. (2010). Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology 28(5):253-261. https://doi.org/10.1016/j.tibtech.2010.02.001
  2. CMC Biotech Working Group. (2009). A-Mab: A Case Study in Bioprocess Development (Version 2.1). CASSS / ISPE, Emeryville CA, 30 October 2009. https://ispe.org/sites/default/files/attachments/public/a-mab-case-study-version.pdf
  3. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 312.21 — Phases of an investigation (Investigational New Drug Application). U.S. Code of Federal Regulations, Title 21, Part 312, Subpart B; eCFR current edition. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.21
  4. DiMasi JA, Grabowski HG, Hansen RW. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012
  5. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing (May 20-21, 2014 Continuous Manufacturing Symposium). Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  6. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 211 Subpart J — Records and Reports (incl. 211.188 Batch production and control records). U.S. Code of Federal Regulations, Title 21, Part 211, Subpart J; eCFR current edition. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J
  7. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Current Step 4, August 2009. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
  8. ICH (International Council for Harmonisation). (2008). ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. ICH, Current Step 4, June 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
  9. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry — PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download

Chapter 2 — What is a biologic? (and what is an antibody?)​

  1. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  2. Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497. https://doi.org/10.1038/256495a0
  3. Jefferis R. (2009). Glycosylation as a strategy to improve antibody-based therapeutics. Nature Reviews Drug Discovery 8(3):226-234. https://doi.org/10.1038/nrd2804
  4. Walsh G, Walsh E. (2022). Biopharmaceutical benchmarks 2022. Nature Biotechnology 40(12):1722-1760. https://doi.org/10.1038/s41587-022-01582-x
  5. ICH (International Council for Harmonisation). (2023). ICH Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Harmonised Guideline, Step 4, adopted 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q5A(R2)_Guideline_2023_1101.pdf
  6. ICH (International Council for Harmonisation). (1999). ICH Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline, Step 4 (CPMP/ICH/365/96), adopted 10 March 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  7. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. (2007). Downstream processing of monoclonal antibodies — Application of platform approaches. Journal of Chromatography B 848(1):28-39. https://doi.org/10.1016/j.jchromb.2006.09.026
  8. Kelley B. (2009). Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 1(5):443-452. https://doi.org/10.4161/mabs.1.5.9448
  9. EMA CHMP (Committee for Medicinal Products for Human Use). (2012). Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies — Non-Clinical and Clinical Issues. EMA/CHMP/BMWP/403543/2010, adopted May 2012, effective 1 December 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-and-clinical-issues_en.pdf

Chapter 3 — The big picture: upstream, downstream, fill-finish​

  1. Shukla AA, Thömmes J. (2010). Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology 28(5):253-261. https://doi.org/10.1016/j.tibtech.2010.02.001
  2. Liu HF, Ma J, Winter C, Bayer R. (2010). Recovery and purification process development for monoclonal antibody production. mAbs 2(5):480-499. https://doi.org/10.4161/mabs.2.5.12645
  3. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. (2007). Downstream processing of monoclonal antibodies — Application of platform approaches. Journal of Chromatography B 848(1):28-39. https://doi.org/10.1016/j.jchromb.2006.09.026
  4. ICH (International Council for Harmonisation). (1999). ICH Harmonised Tripartite Guideline Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH, Step 4 (10 March 1999). https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  5. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Step 4 (August 2009). https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  6. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA CDER/CVM/ORA (September 2004). https://www.fda.gov/media/71012/download
  7. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.188 — Batch production and control records (Subpart J, Records and Reports), Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Code of Federal Regulations, Title 21, Part 211, Subpart J. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.188
  8. ASME (American Society of Mechanical Engineers). (2022). ASME BPE-2022: Bioprocessing Equipment. American Society of Mechanical Engineers, New York (ANSI-approved 21 March 2022). https://www.asme.org/codes-standards/find-codes-standards/bpe-bioprocessing-equipment-(1)
  9. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268

Chapter 4 — It starts with a target​

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182. https://doi.org/10.1126/science.3798106
  2. Emmerich CH, Gamboa LM, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, Gerlach B, Hempel K, Bespalov A, Dirnagl U, Parnham MJ. (2021). Improving target assessment in biomedical research: the GOT-IT recommendations. Nature Reviews Drug Discovery 20(1):64-81. https://doi.org/10.1038/s41573-020-0087-3
  3. Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. (2024). Antibodies to watch in 2024. mAbs 16(1):2297450. https://doi.org/10.1080/19420862.2023.2297450
  4. FDA (U.S. Food and Drug Administration), Center for Drug Evaluation and Research. (2007). Guidance for Industry and Review Staff: Target Product Profile — A Strategic Development Process Tool (Draft Guidance). FDA/CDER, Docket FDA-2007-D-0256, March 2007. https://fda.report/media/72566/Target-Product-Profile----A-Strategic-Development-Process-Tool.pdf
  5. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Step 4, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  6. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  7. USP (United States Pharmacopeia). (2024). USP General Chapter <129> Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodies. USP-NF, United States Pharmacopeial Convention. https://doi.usp.org/USPNF/USPNF_M6297_02_01.html
  8. Konstantinov KB, Cooney CL. (2015). White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  9. University of Delaware (UDaily); Lee K (NIIMBL). (2024). Focused on the future — SABRE Center (Securing American Biomanufacturing Research and Education) groundbreaking with NIIMBL. UDaily, University of Delaware, 22 April 2024. https://www.udel.edu/udaily/2024/april/biopharmaceutical-manufacturing-research-education-center-sabre-niimbl/

Chapter 5 — Finding the antibody​

  1. Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497. https://doi.org/10.1038/256495a0
  2. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301):552-554. https://doi.org/10.1038/348552a0
  3. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069):522-525. https://doi.org/10.1038/321522a0
  4. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proceedings of the National Academy of Sciences USA 86(24):10029-10033. https://doi.org/10.1073/pnas.86.24.10029
  5. Frenzel A, Schirrmann T, Hust M. (2016). Phage display-derived human antibodies in clinical development and therapy. mAbs 8(7):1177-1194. https://doi.org/10.1080/19420862.2016.1212149
  6. Carter PJ. (2006). Potent antibody therapeutics by design. Nature Reviews Immunology 6(5):343-357. https://doi.org/10.1038/nri1837
  7. Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, Vásquez M, Wittrup KD. (2017). Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences USA 114(5):944-949. https://doi.org/10.1073/pnas.1616408114
  8. ICH (International Council for Harmonisation). (2011). ICH Harmonised Tripartite Guideline S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH, Step 4 (parent guideline 1997; R1 addendum incorporated June 2011). https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf
  9. FDA (U.S. Food and Drug Administration), Center for Biologics Evaluation and Research. (1997). Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. FDA/CBER, Docket 94D-0259, February 28, 1997. https://www.govinfo.gov/content/pkg/GOVPUB-HE20_4000-PURL-LPS113624/pdf/GOVPUB-HE20_4000-PURL-LPS113624.pdf

Chapter 6 — Building the factory cell​

  1. Wurm FM. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology 22(11):1393-1398. https://doi.org/10.1038/nbt1026
  2. Lai T, Yang Y, Ng SK. (2013). Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production. Pharmaceuticals 6(5):579-603. https://doi.org/10.3390/ph6050579
  3. Frye C, Deshpande R, Estes S, Francissen K, Joly J, Lubiniecki A, Munro T, Russell R, Wang T, Anderson K. (2016). Industry view on the relative importance of "clonality" of biopharmaceutical-producing cell lines. Biologicals 44(2):117-122. https://doi.org/10.1016/j.biologicals.2016.01.001
  4. Wurm FM, Wurm MJ. (2017). Cloning of CHO Cells, Productivity and Genetic Stability—A Discussion. Processes 5(2):20. https://doi.org/10.3390/pr5020020
  5. ICH (International Council for Harmonisation). (1997). ICH Q5D: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline, CPMP/ICH/294/95, Step 4 (16 July 1997). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-d-derivation-and-characterisation-cell-substrates-used-production-biotechnologicalbiological-products-step-5_en.pdf
  6. ICH (International Council for Harmonisation). (2023). ICH Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Harmonised Guideline, Step 4 (1 November 2023). https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf
  7. WHO (World Health Organization). (2013). Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks (TRS 978, Annex 3). WHO Technical Report Series No. 978, Annex 3 (2013). https://cdn.who.int/media/docs/default-source/biologicals/documents/trs_978_annex_3.pdf
  8. FDA (U.S. Food and Drug Administration), CBER. (2010). Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. U.S. FDA, Center for Biologics Evaluation and Research (February 2010). https://www.fda.gov/media/78428/download
  9. ICH (International Council for Harmonisation). (1995). ICH Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. ICH Harmonised Tripartite Guideline, CPMP/ICH/139/95, Step 4 (30 November 1995). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-b-analysis-expression-construct-cell-lines-used-production-r-dna-derived-protein-products-step-5_en.pdf

Chapter 7 — Perfecting the recipe (process development)​

  1. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Current Step 4 version, August 2009. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
  2. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  3. Xing Z, Kenty BM, Li ZJ, Lee SS. (2009). Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnology and Bioengineering 103(4):733-746. https://doi.org/10.1002/bit.22287
  4. Legmann R, Schreyer HB, Combs RG, McCormick EL, Russo AP, Rodgers ST. (2009). A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnology and Bioengineering 104(6):1107-1120. https://doi.org/10.1002/bit.22474
  5. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. (2007). Downstream processing of monoclonal antibodies — application of platform approaches. Journal of Chromatography B 848(1):28-39. https://doi.org/10.1016/j.jchromb.2006.09.026
  6. ICH (International Council for Harmonisation). (2012). ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). ICH, Current Step 4 version, 1 May 2012. https://database.ich.org/sites/default/files/Q11%20Guideline.pdf
  7. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA, CDER/CVM/ORA, September 2004 (notice of availability October 2004). https://www.fda.gov/media/71012/download
  8. USP (U.S. Pharmacopeia). (2017). General Chapter <1132> Residual Host Cell Protein Measurement in Biopharmaceuticals. United States Pharmacopeia–National Formulary (USP-NF), USP 39 published version, January 2017. https://www.usp.org/sites/default/files/usp/document/our-work/biologics/USPNF810G-GC-1132-2017-01.pdf
  9. CMC Biotech Working Group. (2009). A-Mab: A Case Study in Bioprocess Development (Version 2.1). CASSS / ISPE, 30 October 2009. https://ispe.org/sites/default/files/initiatives/pqli/a-mab-case-study-version.pdf

Chapter 8 — Measuring quality and keeping the protein stable​

  1. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianférani S. (2013). Characterization of Therapeutic Antibodies and Related Products. Analytical Chemistry 85(2):715-736. https://doi.org/10.1021/ac3032355
  2. ICH (International Council for Harmonisation). (1999). ICH Harmonised Tripartite Guideline Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH, Step 4 version, 10 March 1999 (CPMP/ICH/365/96). https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  3. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. ICH, Step 4, adopted 1 November 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5-revision-1_en.pdf
  4. ICH (International Council for Harmonisation). (2003). ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH, Step 4 version, 6 February 2003. https://database.ich.org/sites/default/files/Q1A(R2)%20Guideline.pdf
  5. FDA (U.S. Food and Drug Administration), CDER/CVM/ORA. (2004). Guidance for Industry — PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA, Final, October 2004 (Docket FDA-2003-D-0032). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance
  6. USP (U.S. Pharmacopeia). (2017). General Chapter <1225> Validation of Compendial Procedures. United States Pharmacopeia–National Formulary (USP-NF), official 1 August 2017. https://doi.usp.org/USPNF/USPNF_M99945_04_01.html
  7. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.192 — Production record review. U.S. Code of Federal Regulations, Title 21, Part 211, Subpart J. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.192
  8. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, et al. (2009). Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. Journal of Pharmaceutical Sciences 98(4):1201-1205. https://doi.org/10.1002/jps.21530
  9. Wang W, Singh S, Zeng DL, King K, Nema S. (2007). Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences 96(1):1-26. https://doi.org/10.1002/jps.20727

Chapter 9 — From the lab bench to the factory floor​

  1. García-Ochoa F, Gómez E. (2009). Bioreactor scale-up and oxygen transfer rate in microbial processes: An overview. Biotechnology Advances 27(2):153-176. https://doi.org/10.1016/j.biotechadv.2008.10.006
  2. Papoutsakis ET. (1991). Fluid-mechanical damage of animal cells in bioreactors. Trends in Biotechnology 9(12):427-437. https://doi.org/10.1016/0167-7799(91)90145-8
  3. Shukla AA, Thömmes J. (2010). Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology 28(5):253-261. https://doi.org/10.1016/j.tibtech.2010.02.001
  4. Xu J, Xu X, Huang C, Angelo J, Oliveira CL, Xu M, Xu X, Temel D, Ding J, Ghose S, Borys MC, Li ZJ. (2020). Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study. mAbs 12(1):1770669. https://doi.org/10.1080/19420862.2020.1770669
  5. CMC Biotech Working Group. (2009). A-Mab: A Case Study in Bioprocess Development, Version 2.1. CASSS / ISPE, Emeryville, CA, 30 October 2009. https://ispe.org/sites/default/files/initiatives/pqli/a-mab-case-study-version.pdf
  6. ICH (International Council for Harmonisation). (2012). ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). ICH, Step 4, 1 May 2012. https://database.ich.org/sites/default/files/Q11%20Guideline.pdf
  7. FDA (U.S. Food and Drug Administration). (2011). Guidance for Industry: Process Validation: General Principles and Practices. FDA CDER/CBER/CVM, Current Good Manufacturing Practices, Revision 1, January 2011. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices
  8. University of Delaware (UDaily). (2024). Focused on the future: UD breaks ground on the SABRE Center, a pilot-scale cGMP biopharmaceutical manufacturing facility supporting NIIMBL. UDaily, University of Delaware, 25 April 2024. https://www.udel.edu/udaily/2024/april/biopharmaceutical-manufacturing-research-education-center-sabre-niimbl/

Chapter 10 — Waking up the cells: the seed train​

  1. ICH (International Council for Harmonisation). (1997). Q5D: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline, Current Step 4 version, 16 July 1997. https://database.ich.org/sites/default/files/Q5D%20Guideline.pdf
  2. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. FDA CDER/CBER/ORA, September 2004. https://www.fda.gov/media/71026/download
  3. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 211, Subpart J — Records and Reports (Current Good Manufacturing Practice for Finished Pharmaceuticals). U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211, §§211.180–211.198. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J
  4. USP (United States Pharmacopeia). (2017). General Chapter 〈63〉 Mycoplasma Tests. USP-NF, Rockville, MD: United States Pharmacopeia. https://doi.usp.org/USPNF/USPNF_M3687_01_01.html
  5. USP (United States Pharmacopeia). (2017). General Chapter 〈71〉 Sterility Tests. USP-NF, Rockville, MD: United States Pharmacopeia. https://doi.usp.org/USPNF/USPNF_M98810_01_01.html
  6. Drexler HG, Uphoff CC. (2002). Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39(2):75–90. https://doi.org/10.1023/A:1022913015916
  7. Dahodwala H, Lee KH. (2019). The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Current Opinion in Biotechnology 60:128–137. https://doi.org/10.1016/j.copbio.2019.01.011
  8. Pohlscheidt M, Jacobs M, Wolf S, Thiele J, Jockwer A, Gabelsberger J, Jenzsch M, Tebbe H, Burg J. (2013). Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors. Biotechnology Progress 29(1):222–229. https://doi.org/10.1002/btpr.1672
  9. University of Delaware / NIIMBL. (2024). University of Delaware breaks ground on the SABRE Center (Securing American Biomanufacturing Research and Education). UDaily, University of Delaware, 25 April 2024. https://www.udel.edu/udaily/2024/april/biopharmaceutical-manufacturing-research-education-center-sabre-niimbl/

Chapter 11 — The main event: the production bioreactor​

  1. Bielser J-M, Wolf M, Souquet J, Broly H, Morbidelli M. (2018). Perfusion mammalian cell culture for recombinant protein manufacturing - A critical review. Biotechnology Advances 36(4):1328-1340. https://doi.org/10.1016/j.biotechadv.2018.04.011
  2. Garcia-Ochoa F, Gomez E. (2009). Bioreactor scale-up and oxygen transfer rate in microbial processes: an overview. Biotechnology Advances 27(2):153-176. https://doi.org/10.1016/j.biotechadv.2008.10.006
  3. CMC Biotech Working Group (CASSS / ISPE). (2009). A-Mab: A Case Study in Bioprocess Development (Version 2.1). CASSS and ISPE, 30 October 2009. https://ispe.org/sites/default/files/attachments/public/a-mab-case-study-version.pdf
  4. Clincke M-F, Molleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V. (2013). Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell density on the process. Biotechnology Progress 29(3):754-767. https://doi.org/10.1002/btpr.1704
  5. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Current Step 4 version, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  6. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q9(R1): Quality Risk Management. ICH, Step 4 version, adopted 18 January 2023. https://database.ich.org/sites/default/files/ICH_Q9(R1)_Guideline_Step4_2022_1219.pdf
  7. Roberts KB (University of Delaware, UDaily). (2024). Focused on the future: University of Delaware breaks ground on the SABRE Center, a pilot-scale cGMP biomanufacturing facility. UDaily, University of Delaware, 25 April 2024 (groundbreaking held 22 April 2024). https://www.udel.edu/udaily/2024/april/biopharmaceutical-manufacturing-research-education-center-sabre-niimbl/
  8. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry - PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  9. Abu-Absi NR, Kenty BM, Cuellar ME, Borys MC, Sakhamuri S, Strachan DJ, Hausladen MC, Li ZJ. (2011). Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnology and Bioengineering 108(5):1215-1221. https://doi.org/10.1002/bit.23023

Chapter 12 — Harvest: separating cells from the medicine​

  1. Shukla AA, Kandula JR. (2008). Harvest and Recovery of Monoclonal Antibodies from Large-Scale Mammalian Cell Culture. BioPharm International 21(5):34-45. https://www.biopharminternational.com/view/harvest-and-recovery-monoclonal-antibodies-large-scale-mammalian-cell-culture
  2. Roush DJ, Lu Y. (2008). Advances in Primary Recovery: Centrifugation and Membrane Technology. Biotechnology Progress 24(3):488-495. https://doi.org/10.1021/bp070414x
  3. Singh N, Arunkumar A, Chollangi S, Tan ZG, Borys M, Li ZJ. (2016). Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives. Biotechnology and Bioengineering 113(4):698-716. https://doi.org/10.1002/bit.25810
  4. ICH (International Council for Harmonisation). (1999). Q6B: Specifications - Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline, Step 4, 10 March 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  5. FDA (U.S. Food and Drug Administration). (2008). 21 CFR 211.67 - Equipment cleaning and maintenance (Current Good Manufacturing Practice for Finished Pharmaceuticals). U.S. Code of Federal Regulations, Title 21, Part 211, Subpart D. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-D/section-211.67
  6. ICH (International Council for Harmonisation). (2023). Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Harmonised Guideline, Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf
  7. Shukla AA, Thommes J. (2010). Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology 28(5):253-261. https://doi.org/10.1016/j.tibtech.2010.02.001
  8. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  9. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26

Chapter 13 — Capture: grabbing the antibody (Protein A)​

  1. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. (2007). Downstream processing of monoclonal antibodies — application of platform approaches. Journal of Chromatography B 848(1):28-39. https://doi.org/10.1016/j.jchromb.2006.09.026
  2. Hober S, Nord K, Linhult M. (2007). Protein A chromatography for antibody purification. Journal of Chromatography B 848(1):40-47. https://doi.org/10.1016/j.jchromb.2006.09.030
  3. Linhult M, Gulich S, Graslund T, Simon A, Karlsson M, Sjoberg A, Nord K, Hober S. (2004). Improving the tolerance of a Protein A analogue to repeated alkaline exposures using a bypass mutagenesis approach. Proteins: Structure, Function, and Bioinformatics 55(2):407-416. https://doi.org/10.1002/prot.10616
  4. ICH (International Council for Harmonisation). (1999). Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline, Step 4, 10 March 1999 (EU ref. CPMP/ICH/365/96). https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  5. Girard V, Hilbold N-J, Ng CKS, Pegon L, Chahim W, Rousset F, Monchois V. (2015). Large-scale monoclonal antibody purification by continuous chromatography, from process design to scale-up. Journal of Biotechnology 213:65-73. https://doi.org/10.1016/j.jbiotec.2015.04.026
  6. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  7. Kelley B. (2009). Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 1(5):443-452. https://doi.org/10.4161/mabs.1.5.9448
  8. ICH (International Council for Harmonisation). (2023). Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Harmonised Guideline, Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q5A(R2)_Guideline_2023_1101.pdf
  9. GEN (Genetic Engineering & Biotechnology News). (2024). University of Delaware Breaks Ground on SABRE Center Biomanufacturing Facility. Genetic Engineering & Biotechnology News, 26 April 2024. https://www.genengnews.com/topics/bioprocessing/university-of-delaware-breaks-ground-on-sabre-center-biomanufacturing-facility/

Chapter 14 — Viral safety step 1: low-pH inactivation​

  1. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH, Step 4 / adopted 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf
  2. FDA (U.S. Food and Drug Administration), CDER/CBER. (2024). Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin; Guidance for Industry. FDA, January 2024 (Docket FDA-2022-D-2512). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin
  3. ASTM International (Committee E55). (2012). ASTM E2888-12: Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM International, West Conshohocken, PA (reapproved 2019, 2025). https://store.astm.org/e2888-12r19.html
  4. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. (2003). Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnology and Bioengineering 82(3):321-329. https://doi.org/10.1002/bit.10574
  5. Mattila J, Clark M, Liu S, Pieracci J, Gervais TR, Wilson E, Galperina O, Li X, Roush D, Zoeller K, Brough H, Simpson-Platre C. (2016). Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA Journal of Pharmaceutical Science and Technology 70(3):293-299. https://doi.org/10.5731/pdajpst.2016.006478
  6. Jin W, Xing Z, Song Y, Huang C, Xu X, Ghose S, Li ZJ. (2019). Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification. mAbs 11(8):1479-1491. https://doi.org/10.1080/19420862.2019.1658493
  7. Klutz S, Lobedann M, Bramsiepe C, Schembecker G. (2016). Continuous viral inactivation at low pH value in antibody manufacturing. Chemical Engineering and Processing: Process Intensification 102:88-101. https://doi.org/10.1016/j.cep.2016.01.002
  8. Brown M, Godfrey S, Creasy A, Salm J, Fahrner R. (2022). Continuous low pH viral inactivation: Operation and scaling strategy informs viral clearance study. Biotechnology and Bioengineering 119(8):2115-2121. https://doi.org/10.1002/bit.28117
  9. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.192 - Production record review (Current Good Manufacturing Practice for Finished Pharmaceuticals). U.S. Code of Federal Regulations, Title 21, Part 211, Subpart J. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.192

Chapter 15 — Polishing: removing the last impurities​

  1. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. (2007). Downstream processing of monoclonal antibodies—Application of platform approaches. Journal of Chromatography B 848(1):28–39. https://doi.org/10.1016/j.jchromb.2006.09.026
  2. Liu HF, Ma J, Winter C, Bayer R. (2010). Recovery and purification process development for monoclonal antibody production. mAbs 2(5):480–499. https://doi.org/10.4161/mabs.2.5.12645
  3. Hober S, Nord K, Linhult M. (2007). Protein A chromatography for antibody purification. Journal of Chromatography B 848(1):40–47. https://doi.org/10.1016/j.jchromb.2006.09.030
  4. Pezzini J, Joucla G, Gantier R, Toueille M, Lomenech AM, Le Sénéchal C, Garbay B, Santarelli X, Cabanne C. (2011). Antibody capture by mixed-mode chromatography: A comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins. Journal of Chromatography A 1218(45):8197–8208. https://doi.org/10.1016/j.chroma.2011.09.036
  5. ICH (International Council for Harmonisation). (1999). ICH Harmonised Tripartite Guideline Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH, Step 4 (10 March 1999); EMA ref CPMP/ICH/365/96, effective 1 Sep 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  6. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 610 — General Biological Products Standards. U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter F. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610
  7. Zydney AL. (2016). Continuous downstream processing for high value biological products: A Review. Biotechnology and Bioengineering 113(3):465–475. https://doi.org/10.1002/bit.25695
  8. Nitika N, Thakur G, Rathore AS. (2023). Continuous manufacturing of monoclonal antibodies: Dynamic control of multiple integrated polishing chromatography steps using BioSMB. Journal of Chromatography A 1690:463784. https://doi.org/10.1016/j.chroma.2023.463784

Chapter 16 — Viral safety step 2: filtering viruses out​

  1. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH, Step 4 adopted 1 November 2023; FDA Guidance for Industry, January 2024 (Docket FDA-2022-D-2512). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin
  2. PDA (Parenteral Drug Association) Virus Filtration Task Force. (2022). Technical Report No. 41 (Revised 2022): Virus Filtration. PDA Technical Report Series, Parenteral Drug Association, Bethesda, MD (ISBN 978-1-945584-34-3). https://www.pda.org/bookstore/product-detail/6725-tr-41-revised-virus-filtration
  3. USP (United States Pharmacopeia). (2016). General Chapter <1050.1> Design, Evaluation, and Characterization of Viral Clearance Procedures. United States Pharmacopeia–National Formulary (USP–NF), Rockville, MD. https://doi.usp.org/USPNF/USPNF_M7187_01_01.html
  4. Lute S, Aranha H, Tremblay D, Liang D, Ackermann H-W, Chu B, Moineau S, Brorson K. (2004). Characterization of Coliphage PR772 and Evaluation of Its Use for Virus Filter Performance Testing. Applied and Environmental Microbiology 70(8):4864–4871. https://doi.org/10.1128/AEM.70.8.4864-4871.2004
  5. EDQM (European Directorate for the Quality of Medicines & HealthCare). (2008). European Pharmacopoeia General Chapter 5.1.7: Viral Safety. European Pharmacopoeia (Ph. Eur.), reference 01/2008:50107, Council of Europe, Strasbourg. https://www.drugfuture.com/Pharmacopoeia/EP7/DATA/50107E.PDF
  6. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 610 — General Biological Products Standards (Subpart B, General Provisions, §§ 610.10–610.14: potency, general safety, sterility, purity, identity). U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter F, Part 610, Subpart B (eCFR). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610/subpart-B
  7. Bohonak DM, Mehta U, Weiss ER, Voyta G. (2021). Adapting virus filtration to enable intensified and continuous monoclonal antibody processing. Biotechnology Progress 37(2):e3088. https://doi.org/10.1002/btpr.3088

Chapter 17 — Final concentration: making the drug substance​

  1. van Reis R, Zydney A. (2007). Bioprocess membrane technology. Journal of Membrane Science 297(1-2):16-50. https://doi.org/10.1016/j.memsci.2007.02.045
  2. Rosenberg E, Hepbildikler S, Kuhne W, Winter G. (2009). Ultrafiltration concentration of monoclonal antibody solutions: Development of an optimized method minimizing aggregation. Journal of Membrane Science 342(1-2):50-59. https://doi.org/10.1016/j.memsci.2009.06.028
  3. Wang W, Singh S, Zeng DL, King K, Nema S. (2007). Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences 96(1):1-26. https://doi.org/10.1002/jps.20727
  4. ICH (International Council for Harmonisation). (1999). ICH Harmonised Tripartite Guideline Q6B: Specifications - Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH, Step 4, 10 March 1999. https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  5. USP (United States Pharmacopeial Convention). (2014). USP General Chapter <787> Subvisible Particulate Matter in Therapeutic Protein Injections. United States Pharmacopeia and National Formulary (USP-NF), official 1 August 2014. https://doi.usp.org/USPNF/USPNF_M6497_02_01.html
  6. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.72 Filters (Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart D - Equipment). U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-D/section-211.72
  7. Zydney AL. (2016). Continuous downstream processing for high value biological products: A Review. Biotechnology and Bioengineering 113(3):465-475. https://doi.org/10.1002/bit.25695
  8. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268

Chapter 18 — Fill-finish: from bulk to vials (drug product)​

  1. European Commission (EudraLex Volume 4, EU GMP). (2022). Annex 1: Manufacture of Sterile Medicinal Products. EudraLex - The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines for Good Manufacturing Practice; Brussels, 22.8.2022 C(2022) 5938 final; in operation 25 Aug 2023 (point 8.123 from 25 Aug 2024). https://health.ec.europa.eu/latest-updates/revision-manufacture-sterile-medicinal-products-2022-08-25_en
  2. FDA (U.S. Food and Drug Administration), CDER/CBER/ORA. (2004). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice. U.S. FDA, Pharmaceutical Quality/Manufacturing Standards (CGMP), September 2004. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice
  3. U.S. Code of Federal Regulations (FDA). (2024). 21 CFR 211.113 - Control of microbiological contamination. Title 21, Chapter I, Subchapter C, Part 211, Subpart F (Production and Process Controls); current eCFR edition. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-F/section-211.113
  4. PDA (Parenteral Drug Association). (2025). Technical Report No. 26 (Revised 2025): Sterilizing Filtration of Liquids. Parenteral Drug Association (PDA), Bethesda, MD; PDA Technical Report TR-26, released Nov 2025. https://www.pda.org/bookstore/product-detail/8489-tr-no-26-revised-2025-sterilizing-filtration
  5. Wang W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics 185(2):129-188. https://doi.org/10.1016/S0378-5173(99)00152-0
  6. Wang W. (2000). Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics 203(1-2):1-60. https://doi.org/10.1016/S0378-5173(00)00423-3
  7. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, et al. (2009). Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. Journal of Pharmaceutical Sciences 98(4):1201-1205. https://doi.org/10.1002/jps.21530
  8. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q9(R1): Quality Risk Management. ICH, Step 4, adopted 18 January 2023. https://database.ich.org/sites/default/files/ICH_Q9(R1)_Guideline_Step4_2022_1219.pdf

Chapter 19 — Packaging, labeling and serialization​

  1. WHO (World Health Organization). (2024). Substandard and falsified medical products (fact sheet). World Health Organization, Geneva; fact sheet, updated 2024. https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products
  2. FDA (U.S. Food and Drug Administration), CDER/CBER/CVM. (2021). Inspection of Injectable Products for Visible Particulates; Draft Guidance for Industry. U.S. FDA, December 2021 (Docket FDA-2021-D-0241; announced 86 FR 71648, 17 Dec 2021); draft. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-injectable-products-visible-particulates
  3. USP (United States Pharmacopeia). (2024). General Chapters <790> Visible Particulates in Injections and <1790> Visual Inspection of Injections. United States Pharmacopeia-National Formulary (USP-NF), Rockville, MD. https://doi.usp.org/USPNF/USPNF_M7197_01_01.html
  4. ISO/IEC (International Organization for Standardization / International Electrotechnical Commission). (2006). ISO/IEC 16022:2006 Information technology - Automatic identification and data capture techniques - Data Matrix bar code symbology specification. ISO/IEC JTC 1/SC 31, Geneva (2nd ed.; superseded by ISO/IEC 16022:2024). https://www.iso.org/standard/44230.html
  5. GS1. (2024). GS1 General Specifications (Release 24.0, January 2024). GS1 AISBL, Brussels; foundational AIDC standard defining Application Identifiers and data carriers (current release at ref.gs1.org). https://ref.gs1.org/standards/genspecs/
  6. FDA (U.S. Food and Drug Administration). (2013). Drug Supply Chain Security Act (DSCSA), Title II of the Drug Quality and Security Act (Pub. L. 113-54). U.S. FDA; signed into law 27 Nov 2013, with package-level interoperable electronic tracing required from 27 Nov 2023. https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
  7. European Commission. (2016). Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use. Official Journal of the European Union L 32, 9 Feb 2016, pp. 1-27 (implementing the Falsified Medicines Directive 2011/62/EU). https://eur-lex.europa.eu/eli/reg_del/2016/161/oj/eng
  8. ICH (International Council for Harmonisation). (1995). ICH Harmonised Tripartite Guideline Q5C: Quality of Biotechnological Products - Stability Testing of Biotechnological/Biological Products. ICH, Current Step 4, 30 November 1995 (EMA ref. CPMP/ICH/138/95). https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf

Chapter 20 — Quality control and batch release​

  1. ICH (International Council for Harmonisation). (1999). ICH Harmonised Tripartite Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH, Step 4 version dated 10 March 1999 (CPMP/ICH/365/96). https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
  2. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 211, Subpart I - Laboratory Controls (Sections 211.160-211.167): General requirements; Testing and release for distribution; Special testing requirements. U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211, Subpart I. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I
  3. USP (United States Pharmacopeial Convention). (2024). General Chapter <71> Sterility Tests. United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org/harmonization-standards/pdg/general-methods/sterility-test
  4. USP (United States Pharmacopeial Convention). (2024). General Chapter <85> Bacterial Endotoxins Test. United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org/harmonization-standards/pdg/general-methods/bacterial-endotoxins
  5. FDA (U.S. Food and Drug Administration). (2012). Guidance for Industry: Pyrogen and Endotoxins Testing - Questions and Answers. FDA CDER/CBER/CVM, June 2012. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers
  6. USP (United States Pharmacopeial Convention). (2013). General Chapter <1033> Biological Assay Validation. United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org/biologics/bioassays
  7. European Commission. (2015). EudraLex Volume 4, EU GMP Guide Annex 16: Certification by a Qualified Person and Batch Release. European Commission, EU Guidelines for Good Manufacturing Practice; effective 15 April 2016. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  8. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  9. Eon-Duval A, Broly H, Gleixner R. (2012). Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnology Progress 28(3):608-622. https://doi.org/10.1002/btpr.1548

Chapter 21 — The last mile: cold-chain to the patient​

  1. ICH (International Council for Harmonisation). (1995). ICH Harmonised Tripartite Guideline Q5C: Quality of Biotechnological Products — Stability Testing of Biotechnological/Biological Products. ICH, Step 4 version, 30 November 1995. https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf
  2. ICH (International Council for Harmonisation). (2003). ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH, Step 4 version, 6 February 2003. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
  3. Wang W, Singh S, Zeng DL, King K, Nema S. (2007). Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences 96(1):1-26. https://doi.org/10.1002/jps.20727
  4. WHO (World Health Organization). (2011). Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (Annex 9). WHO Technical Report Series No. 961, Annex 9, 2011. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs961-annex9-modelguidanceforstoragetransport.pdf
  5. European Commission. (2013). Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01). Official Journal of the European Union C 343, 23.11.2013, pp. 1-14. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C_.2013.343.01.0001.01.ENG
  6. PDA (Parenteral Drug Association). (2005). Technical Report No. 39: Cold Chain Guidance for Medicinal Products — Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment. PDA Journal of Pharmaceutical Science and Technology 59(3 Suppl TR39):1-12. https://pubmed.ncbi.nlm.nih.gov/16313059/
  7. USP (United States Pharmacopeia). (2021). General Chapter <1079> Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug Products. United States Pharmacopeia–National Formulary (USP-NF), official 1 February 2021. https://www.usp.org/sites/default/files/usp/document/supply-chain/apec-toolkit/USP%20GC1079.pdf
  8. U.S. Code of Federal Regulations. (2024). 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals: §211.150 Distribution procedures and §211.192 Production record review. Title 21, Chapter I, Subchapter C, Part 211, Subparts H and J (eCFR). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.192

Chapter 22 — The framework around everything: quality, rules, and data​

  1. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Current Step 4 version, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  2. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  3. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System (Guidance for Industry). ICH Step 4 (June 2008); FDA CDER/CBER guidance issued April 2009. https://www.fda.gov/media/71553/download
  4. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA, CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  5. U.S. Code of Federal Regulations. (2025). 21 CFR Part 11 - Electronic Records; Electronic Signatures. Title 21, Chapter I, Subchapter A, Part 11 (Subparts A-C, §§11.1-11.300). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
  6. FDA (U.S. Food and Drug Administration). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. FDA, CDER/CBER/CVM, December 2018. https://www.fda.gov/media/119267/download
  7. ISPE (International Society for Pharmaceutical Engineering). (2023). ISPE Baseline Guide Volume 8: Pharma 4.0 (First Edition). ISPE, Tampa FL, 1st Edition, December 2023 (DOI 10.1002/9781946964724). https://ispe.org/publications/guidance-documents/baseline-guide-vol-8-pharma-40-1st-edition
  8. NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals). (2024). NIIMBL and Open Applications Group (OAGi) partner to develop open-source biopharmaceutical manufacturing ontologies. NIIMBL News, 13 June 2024 (Industrial Ontologies Foundry / BMIC). https://www.niimbl.org/news/niimbl-and-open-applications-group-oagi-partner-to-develop-open-source-biopharmaceutical-manufacturing-ontologies/
  9. DiMasi JA, Grabowski HG, Hansen RW. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012

Image credits & colophon​

Sources and licenses for every image used in this guide. Photographs are reproduced under the stated public-domain or Creative Commons terms, with attribution. Every schematic marked “Original diagram by the authors” was created by the authors with AI assistance and may be reproduced with attribution. A final legal review is recommended before commercial print publication.

  • “The two timescales of biologic manufacturing: one-time approval journey versus repeating batch cycle, each governed by cGMP and Quality by Design”. Original diagram by the authors, created with AI assistance.
  • “The anatomy of a monoclonal antibody: a Y-shaped protein ~150 kDa in mass, with two identical antigen-binding arms (Fab regions) and one signaling tail (Fc region). The glycosylation site (green) at Asn297 modulates immune response. Every copy from the same cell line is identical”. Original diagram by the authors, created with AI assistance.
  • “Fed-batch monolithic-batch processing (left) vs. continuous intensified perfusion with multi-column capture (right): differences in bioreactor operation, capture dynamics, process duration, and yield”. Original diagram by the authors, created with AI assistance.
  • “The Target Product Profile (TPP) is a comprehensive wish-list that documents disease indication, patient demographics, dose and route, shelf-life and storage conditions, and quality/potency targets. Every parameter in the TPP cascades into manufacturing choices downstream”. Original diagram by the authors, created with AI assistance.
  • “Two routes to antibody discovery: immunization-driven hybridoma generation (left) versus in vitro phage display (right) both converge at a lead-selection funnel, where affinity, stability, and developability metrics narrow thousands of candidates to the single DNA sequence that seeds manufacturing”. Original diagram by the authors, created with AI assistance.
  • Adherent CHO cells under phase-contrast microscopy. Image by Alcibiades, public domain, via Wikimedia Commons.
  • “Single-cell cloning ensures clonality and consistency. Unlike early industrial pools, modern pharma cell lines originate from one founder cell, tested for high titer, low aggregates, and genetic stability before being frozen into Master (MCB) and Working (WCB) cell banks”. Original diagram by the authors, created with AI assistance.
  • Benchtop bioreactor cultivating animal cells. Image by Karel Schmiedberger ml., CC BY 3.0, via Wikimedia Commons.
  • “Typical mAb manufacturing process development pathway: fed-batch culture (left) with key parameters monitored, connected to multi-step chromatography capture and polishing (right). Arrows indicate material flow; callout boxes show CQAs and CPPs tracked at each stage”. Original diagram by the authors, created with AI assistance.
  • Q-TOF LC/MS mass spectrometer. Image by Michael Pereckas, CC BY 2.0, via Wikimedia Commons.
  • “The analytical testing cascade ensures every critical quality attribute is measured and stays within specification from development through manufacturing release”. Original diagram by the authors, created with AI assistance.
  • “Scale-up challenges: oxygen, mixing, and shear. The left flask achieves uniform conditions; the large tank (right) has depth-dependent oxygen, slow mixing fronts, and high shear near the impeller”. Original diagram by the authors, created with AI assistance.
  • Culture flasks in an incubator shaker. Image by Diane A. Reid (National Cancer Institute), public domain, via Wikimedia Commons.
  • “The seed train physically progresses from a 1–2 mL frozen vial (WCB) through shake flasks (125 mL), wave bioreactors (2–5 L), and seed bioreactors (10–20 L) over 4–7 days in fed-batch mode. Each step maintains aseptic conditions and controlled parameters (temperature, pH, dissolved oxygen) to protect cell viability and purity”. Original diagram by the authors, created with AI assistance.
  • “A production bioreactor cross-section with integrated control loop: sensors feed the controller, which adjusts heater, agitation, and feed pumps to hold setpoints. Inset compares stainless-steel stirred-tank (fed-batch) to single-use bag (perfusion).”. Original diagram by the authors, created with AI assistance.
  • “Two-stage harvest: disk-stack centrifugation (left) uses 10,000–20,000 g to sediment cells radially, while depth filtration (right) traps fine impurities throughout a layered media matrix. Modern systems integrate both into a single cGMP-compliant skid with in-line monitoring of temperature, pressure, and clarity”. Original diagram by the authors, created with AI assistance.
  • “The Protein A capture cycle: bind the antibody by its Fc stem, wash impurities to waste, release a concentrated pool at low pH, then clean and reuse the column”. Original diagram by the authors, created with AI assistance.
  • “Low-pH inactivation can be performed as batch hold in a monitored tank or continuous residence in a coil; both achieve same kill kinetics but differ in footprint and throughput model”. Original diagram by the authors, created with AI assistance.
  • “Polishing chromatography column: antibody (Y-shape) and impurities (HCP, aggregate, DNA) enter the resin bed. Ion-exchange beads bind impurities or antibody depending on pH and salt; product is collected as a peak elution”. Original diagram by the authors, created with AI assistance.
  • “Virus-retentive nanofilter architecture and mechanism: antibodies (10 nm) pass through, viruses (>20 nm) are trapped, and membrane fouling reduces flow rate over time”. Original diagram by the authors, created with AI assistance.
  • “TFF system showing sideways cross-flow sweeping a permeable membrane, with retentate (concentrated antibody) exiting above and permeate (water + small molecules) below. Inset contrasts batch hold-and-exchange (hours-long pause) vs. continuous co-fed diafiltration (steady state with buffer pump)”. Original diagram by the authors, created with AI assistance.
  • “Aseptic fill-finish cleanroom layout: the Grade A operation zone (≤3,520 particles/m³) is isolated from Grade B support areas, with unidirectional HEPA airflow and personnel gowning controls to prevent microbial ingress”. Original diagram by the authors, created with AI assistance.
  • “A typical automated packaging line for vials: vision inspection (200–600 units/min), labeling with tamper evidence, and 2D GS1 DataMatrix serialization (shown with sample barcode)”. Original diagram by the authors, created with AI assistance.
  • “The cascade of release tests: a finished vial is sampled and tested in parallel across identity, purity, potency, sterility, endotoxin, and appearance, with results compiled into the Certificate of Analysis and final disposition decision by the Qualified Person”. Original diagram by the authors, created with AI assistance.
  • Refrigerated cold-chain shipping container. Image by U.S. Army Medical Logistics Command, public domain, via Wikimedia Commons.
  • “Validated insulated shipping containers (qualified coolers) are engineered and tested to hold medicines at the target temperature range for a specified duration; temperature data loggers ride inside to prove compliance”. Original diagram by the authors, created with AI assistance.
  • “The shift from end-of-batch testing to real-time quality monitoring: traditional release testing waits weeks; PAT in fed-batch enables mid-process decisions; continuous perfusion enables rolling real-time pooling and disposition”. Original diagram by the authors, created with AI assistance.